New Alzheimer's treatment enters human testing
NCT ID NCT06189963
Summary
This early-stage study aims to test the safety and side effects of an experimental treatment called SNK01 for people with moderate Alzheimer's disease. Researchers will give SNK01 as an intravenous infusion every three weeks for up to one year to 36 participants. The study will also look for early signs that the treatment might help with memory, thinking, and daily activities.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Research Institute
RECRUITINGOrlando, Florida, 32804, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Behavioral Research Specialists, LLC
RECRUITINGGlendale, California, 91206, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ottawa Memory Clinic
NOT_YET_RECRUITINGOttawa, Ontario, K1Z 1G3, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Syrentis Clinical Research
RECRUITINGSanta Ana, California, 92705, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Valiance Clinical Research
RECRUITINGTarzana, California, 91356, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.